Clinical utility of intralesional methotrexate to distinguish crateriform keratinocytic tumors before surgery

J Dtsch Dermatol Ges. 2022 Jan;20(1):102-105. doi: 10.1111/ddg.14637. Epub 2021 Dec 21.

Authors

Rafael Salido-Vallejo^{1

2}, Juan Luis Sanz-Cabanillas², Jorge María Núñez-Córdoba³, Alberto González-Menchen⁴, Antonio Vélez², Pedro Redondo¹

Affiliations

¹ Department of Dermatology, University Clinic of Navarra, School of Medicine, University of Navarra, Pamplona, Spain.
² Department of Dermatology, Reina Sofía University Hospital, Córdoba, Spain.
³ Research Support Service, Central Clinical Trials Unit, University Clinic of Navarra, Pamplona, Spain.
⁴ Department of Pathology, Reina Sofía University Hospital, Córdoba, Spain.

PMID: 34932272
DOI: 10.1111/ddg.14637

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Injections, Intralesional
Keratinocytes
Keratoacanthoma*
Methotrexate / therapeutic use
Neoplasms*

Substances

Methotrexate